FDA
-
-
-
-
-
-
-
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
-
-
-
-
-
-
-
Alto Neuroscience (ANRO) PT Raised to $16 at Baird
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): G
-
-
-
-
-
-
-
Baird Reiterates Outperform Rating on Alto Neuroscience (ANRO)
-
-
330,011 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

